TDMS No. 20107 - 03	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Requested: 02/28/2011
Test Type: CHRONIC	N,N-Dimethyl-p-toluidine	Time Report Requested: 11:17:44
Route: GAVAGE	CAS Number: 99-97-8	First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N		Lab: BAT
	F1_Rev.1R2	

C Number:	C20107
Lock Date:	02/20/2008
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.3.0
PWG Approval Date:	01/25/2011

TDMS No. 20107 - 03	P18: INCIDENCE RATE	Date Report Requested: 02/28/2011			
Test Type: CHRONIC		N,N-Dimeth	yl-p-toluidine		Time Report Requested: 11:17:44
Route: GAVAGE		CAS Numb	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Disposition Summary					
	50	50	50	50	
Animals Initially In Study	50	50	50	50	
Early Deaths				2	
Dosing Accident		1	1	3	
Moribund Sacrifice	11	7	11	7	
Natural Death	2	5	7	19	
Survivors	27	97	24	24	
Terminal Sacrifice Animals Examined Microscopically	37 50	37 50	31 50	21 50	
	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Foreign Body			1		
Inflammation				1 [3.0]	
Perforation			1	2	
Periesophageal Tissue, Inflammation				1 [3.0]	
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Parasite Metazoan	1	2	1		
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Parasite Metazoan	3	5	2	3	
Intestine Small, Duodenum	(50)	(50)	(50)	(50)	
Inflammation, Chronic Active			1 [2.0]		
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Parasite Metazoan			1		
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	
Liver	(50)	(50)	(50)	(50)	
Angiectasis	1 [2.0]				
Basophilic Focus	28	6		3	
Clear Cell Focus	30	36	26	35	
Congestion	1 [2.0]				
Degeneration, Cystic	4 [1.3]	10 [1.4]	9 [1.3]	17 [1.3]	
Eosinophilic Focus	11	21	21	29	
Fatty Change, Focal	6 [1.3]	2 [1.0]	3 [1.3]	9 [1.2]	

DMS No. 20107 - 03	P18: INCIDENCE RAT	Date Report Requested: 02/28/2011			
est Type: CHRONIC		Time Report Requested: 11:17:44			
Route: GAVAGE		CAS Num	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
pecies/Strain: RATS/F 344/N					Lab: BAT
ISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Fatty Change, Diffuse	1 [2.0]	8 [1.1]	5 [1.6]	5 [2.0]	
Hematopoietic Cell Proliferation	1 [1.0]	0[]	1 [1.0]	1 [1.0]	
Hemorrhage	1 [2.0]		.[]	.[]	
Hepatodiaphragmatic Nodule	8	1		3	
Inflammation	40 [1.1]	46 [1.1]	42 [1.0]	44 [1.0]	
Mixed Cell Focus	18	17	17	35	
Vacuolization Cytoplasmic	10	1 [2.0]	3 [1.3]	1 [2.0]	
Bile Duct, Cyst		1	3	، <u>ا</u> ۲.0]	
Bile Duct, Fibrosis	21 [1.0]	27 [1.0]	41 [1.1]	42 [1.5]	
Bile Duct, Hyperplasia	40 [1.2]	42 [1.5]	44 [1.6]	44 [1.8]	
Hepatocyte, Hypertrophy	40[1.2]	42 [1.0]	6 [1.5]	31 [1.5]	
Hepatocyte, Necrosis	2 [1.0]		2 [2.0]	1 [1.0]	
Oval Cell, Hyperplasia	2 [1.0]		2 [2.0] 2 [1.5]	2 [1.0]	
Mesentery	(7)	(5)	(2)	(1)	
Fat, Necrosis	7 [2.9]	5 [3.0]	1 [3.0]	1 [3.0]	
Pancreas	(50)	(50)	(50)	(50)	
Basophilic Focus	1 [2.0]	(50)	(50)	(50)	
Cyst	2	4	6	2	
Hyperplasia	Z	1 [3.0]	0	2	
Infiltration Cellular, Mononuclear Cell	16 [1.3]	14 [1.3]	16 [1.2]	20 [1.4]	
Lipomatosis	10 [1:5]	14 [1.3]		20 [1.4]	
•			1 [1.0]	1 [2 0]	
Metaplasia, Hepatocyte	21 [1 0]	10 21 02	17 [1 6]	1 [2.0]	
Acinus, Atrophy	21 [1.8]	20 [2.0]	17 [1.6]	12 [1.7]	
Acinus, Hyperplasia	2 [2.0]	2 [2.5]	1 [3.0]	(50)	
Salivary Glands Infiltration Cellular	(50)	(50)	(50)	(50)	
		1 [1.0]		(50)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Edema	4 [4 0]	1 [2.0]			
Erosion	1 [1.0]	2 [4 7]	F [0, 0]	14 [0 0]	
Hyperplasia, Squamous	4 [0 0]	3 [1.7]	5 [2.2]	11 [2.2]	
Inflammation	1 [2.0]	5 [1.6]	5 [2.6]	7 [2.6]	
Ulcer Stampsh, Clandular		2 [2.0]	5 [2.6]	6 [2.0]	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Erosion	1 [1.0]	4 [0 0]		4 [0 0]	
Inflammation		1 [2.0]	2 [1.5]	1 [2.0]	
Mineralization				2 [1.5]	

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No. 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011			
Test Type: CHRONIC		N,N-Dimeth	yl-p-toluidine		Time Report Requested: 11:17:44
Route: GAVAGE		CAS Num	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Necrosis				1 [3.0]	
Ulcer		1 [2.0]	2 [2.0]	. [0:0]	
Tongue	(0)	(1)	(0)	(1)	
Tooth	(1)	(2)	(2)	(0)	
Dysplasia	(')	(=)	(2)	(0)	
Peridontal Tissue, Inflammation	1 [3.0]	2 [2.0]	1 [2.0]		
CARDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(50)	(50)	
Aorta, Mineralization	()	()	()	1 [2.0]	
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	46 [1.4]	50 [1.3]	49 [1.4]	48 [1.4]	
Mineralization		00[110]		3 [1.3]	
Pigmentation	1 [1.0]			0[1.0]	
Thrombosis	[1:0]		1 [3.0]	2 [3.0]	
Artery, Inflammation		1 [2.0]	1 [0.0]	2 [0.0]	
Pericardium, Inflammation		1 [2.0]		1 [1.0]	
				. [1.0]	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Angiectasis	13 [1.4]	9 [1.2]	7 [1.1]	4 [1.0]	
Hyperplasia	17 [1.4]	21 [1.6]	10 [1.4]	8 [1.5]	
Hypertrophy	9 [1.4]	6 [1.5]	6 [1.7]	7 [1.3]	
Necrosis				1 [2.0]	
Vacuolization Cytoplasmic	31 [1.5]	31 [1.2]	26 [1.3]	28 [1.5]	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia	18 [1.5]	15 [1.9]	12 [1.7]	18 [1.6]	
Infiltration Cellular, Lymphocyte		1 [3.0]			
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	1 [1.0]	2 [2.0]	1 [1.0]		
Parathyroid Gland	(49)	(49)	(45)	(48)	
Cyst	· · ·	1	. ,	. /	
Hyperplasia, Focal	2 [2.0]				
a - Number of animals examined micros		of animals with losio	n		

TDMS No. 20107 - 03	P18: INCIDENCE RATI	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]					
Test Type: CHRONIC		N,N-Dimethy	yl-p-toluidine		Time Report Requested: 11:17:44		
Route: GAVAGE		CAS Numb	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04		
Species/Strain: RATS/F 344/N					Lab: BAT		
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG			
Hyperplasia, Diffuse	1 [2.0]		2 [2.5]	5 [2.0]			
Pituitary Gland	(50)	(50)	(50)	(50)			
Angiectasis		1 [2.0]	(00)				
Cyst	1	2	2	1			
Pars Distalis, Cyst	•	2	1	I			
Pars Distalis, Hemorrhage	1 [3.0]		I				
Pars Distalis, Heriornage Pars Distalis, Hyperplasia		10 10 1	15 [2 2]	18 [1 0]			
Thyroid Gland	15 [2.3]	18 [2.2]	15 [2.3]	18 [1.9]			
-	(50)	(49)	(50)	(49)			
C-cell, Hyperplasia	14 [1.7]	20 [1.5]	14 [1.3]	5 [1.8]			
Follicle, Cyst		1	4.14.01				
Follicular Cell, Hyperplasia			1 [1.0]				
GENERAL BODY SYSTEM							
Tissue NOS	(0)	(0)	(2)	(0)			
GENITAL SYSTEM							
Coagulating Gland	(1)	(2)	(1)	(0)			
Inflammation	1 [4.0]	2 [3.0]	(1)	(0)			
Epithelium, Hyperplasia	1 [3.0]	1 [3.0]					
Epididymis	(50)	(50)	(50)	(50)			
Atypia Cellular	(50)	1 [4.0]	(30)	(50)			
Inflammation		1 [1.0]	2 [1.5]	2 [1.5]			
	(50)						
Preputial Gland	(50)	(50)	(50)	(50) 1			
Cyst	4 [2 0]			•			
Hyperplasia	1 [3.0]	40 [4 0]	40 [4 4]	1 [3.0]			
Inflammation	49 [1.5]	49 [1.6]	43 [1.4]	45 [1.3]			
Prostate	(50)	(50)	(50)	(50)			
Inflammation	23 [1.8]	28 [2.0]	18 [1.6]	16 [1.9]			
Pigmentation				1 [2.0]			
Epithelium, Hyperplasia	2 [1.0]	6 [1.3]	2 [2.0]	3 [1.7]			
Seminal Vesicle	(50)	(50)	(50)	(50)			
Inflammation	1 [3.0]	1 [3.0]		1 [3.0]			
Epithelium, Hyperplasia		1 [4.0]		1 [3.0]			

TDMS No. 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011			
Test Type: CHRONIC			Time Report Requested: 11:17:44		
Route: GAVAGE		CAS Numb	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Testes	(50)	(50)	(50)	(50)	
Cyst	. ,	1			
Mineralization	1 [1.0]		1 [2.0]	1 [2.0]	
Interstitial Cell, Hyperplasia	16 [1.2]	16 [1.4]	6 [1.8]	12 [1.4]	
HEMATOPOIETIC SYSTEM	,				
Bone Marrow	(50)	(50)	(50)	(50)	
Hemorrhage			1 [2.0]	4 [2.3]	
Hyperplasia	17 [2.5]	13 [2.5]	28 [2.1]	50 [2.7]	
Myelofibrosis			1 [2.0]		
Necrosis	1 [2.0]				
Lymph Node	(4)	(3)	(3)	(7)	
Deep Cervical, Hyperplasia, Plasma Cell	1 [2.0]				
Mediastinal, Ectasia		2 [2.0]	2 [2.5]	3 [2.7]	
Mediastinal, Hemorrhage		1 [3.0]			
Mediastinal, Hyperplasia, Lymphoid			1 [2.0]	3 [2.3]	
Mediastinal, Hyperplasia, Plasma Cell		1 [2.0]		1 [3.0]	
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)	
Atrophy		1 [2.0]			
Ectasia				2 [2.5]	
Hyperplasia, Lymphoid	2 [2.0]	1 [4.0]		1 [2.0]	
Hyperplasia, Plasma Cell				1 [2.0]	
Infiltration Cellular, Histiocyte	21 [1.1]	23 [1.4]	30 [1.3]	34 [1.5]	
Spleen	(50)	(50)	(50)	(50)	
Congestion	1 [2.0]	·	•	39 [1.9]	
Hematopoietic Cell Proliferation	34 [1.0]	44 [1.1]	42 [1.5]	44 [1.3]	
Inflammation, Suppurative				2 [1.5]	
Pigmentation	36 [1.1]	48 [1.7]	47 [2.1]	48 [2.0]	
Capsule, Fibrosis	1 [2.0]		2 [1.5]	46 [1.8]	
Capsule, Hemorrhage		1 [3.0]			
Capsule, Hypertrophy, Mesothelium		1 [1.0]	3 [1.0]	39 [1.1]	
Lymphoid Follicle, Atrophy		5 [2.2]	2 [1.5]	19 [2.0]	
Red Pulp, Atrophy			1 [3.0]	8 [2.6]	
Thymus	(50)	(48)	(48)	(47)	

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No. 20107 - 03	P18: INCIDENCE RATE	Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44 First Dose M/F: 10/20/04 / 10/21/04 Lab: BAT			
Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344/N					
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Atrophy Hyperplasia, Lymphoid	44 [2.8]	46 [2.7]	44 [2.5]	44 [2.5] 1 [3.0]	
INTEGUMENTARY SYSTEM					
Mammary Gland Cyst	(50)	(50)	(49)	(50) 1	
Hyperplasia Skin Cyst Epithelial Inclusion Inflammation	(50)	(50)	2 [1.0] (50)	(50) 1 1 [3.0]	
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
NERVOUS SYSTEM					
Brain Demyelination	(50) 1 [2.0]	(50)	(50)	(50)	
Hemorrhage Spinal Cord	1 [2.0] (0)	(1)	(0)	(0)	
RESPIRATORY SYSTEM					
Lung Congestion	(50)	(50)	(50) 1 [3.0]	(50) 3 [2.7]	
Foreign Body Inflammation Mineralization	2 [1.5]	1 5 [1.6]	6 [1.7]	1 [1.0] 1 [1.0]	
Alveolar Epithelium, Hyperplasia Alveolus, Foreign Body	8 [2.8]	9 [2.3]	6 [2.3] 1	6 [2.8]	
Alveolus, Infiltration Cellular, Histiocyte	14 [1.1]	2 [1.0]	5 [1.0]	11 [1.1]	

TDMS No. 20107 - 03	P18: INCIDENCE RATI	I Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44			
Test Type: CHRONIC					
Route: GAVAGE		CAS Numb	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Alveolus, Inflammation, Suppurative				1 [2.0]	
Nose	(50)	(49)	(50)	(49)	
Foreign Body	13	17	11	9	
Inflammation	35 [1.4]	40 [1.6]	38 [1.2]	48 [1.9]	
Glands, Olfactory Epithelium, Dilatation	00[11]	10 [110]	3 [1.0]	49 [2.4]	
Glands, Olfactory Epithelium, Hyperplasia		2 [1.0]	0[110]	48 [1.9]	
Glands, Olfactory Epithelium, Metaplasia		-[]		38 [1.5]	
Glands, Olfactory Epithelium, Necrosis				22 [2.7]	
Glands, Respiratory Epithelium, Dilatation	13 [1.0]	15 [1.0]	19 [1.0]	48 [1.6]	
Glands, Respiratory Epithelium, Hyperplasia	10[1.0]	8 [1.1]	8 [1.5]	41 [1.7]	
Glands, Respiratory Epithelium, Metaplasia, Respiratory	29 [1.0]	39 [1.0]	39 [1.0]	47 [2.6]	
Glands, Transitional Epithelium, Dilatation			5 [1.2]	3 [1.7]	
Glands, Transitional Epithelium, Hyperplasia		1 [1.0]	24 [1.1]	40 [1.6]	
Nerve, Atrophy				15 [1.3]	
Olfactory Epithelium, Accumulation, Hyaline Droplet	49 [2.1]	44 [2.0]	40 [1.7]		
Olfactory Epithelium, Degeneration			1 [2.0]	47 [2.1]	
Olfactory Epithelium, Hyperplasia, Basal Cell		1 [1.0]	2 [1.0]	38 [1.3]	
Olfactory Epithelium, Metaplasia, Respiratory	4 [1.0]	9 [1.4]	9 [1.3]	40 [1.3]	
Respiratory Epithelium, Accumulation, Hyaline Droplet		35 [1.2]	30 [1.4]	8 [1.0]	
Respiratory Epithelium, Hyperplasia	15 [1.2]	29 [1.5]	32 [1.3]	49 [1.6]	
Respiratory Epithelium, Ulcer				1 [2.0]	
Squamous Epithelium, Cyst		1		-	
Transitional Epithelium, Hyperplasia	1 [2.0]	1 [1.0]	11 [1.1]	46 [1.7]	
Trachea	(50)	(50)	(50)	(50)	
Inflammation	3 [1.3]	1 [2.0]	1 [1.0]	3 [1.7]	
Perforation		-	-	1	
Peritracheal Tissue, Inflammation				2 [3.0]	
SPECIAL SENSES SYSTEM					
Eye	(50)	(50)	(50)	(50)	
Dysplasia		1			
Inflammation		1 [2.0]			

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No . 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011			
Test Type: CHRONIC		N,N-Dimeth	yl-p-toluidine		Time Report Requested: 11:17:44
Route: GAVAGE		CAS Num	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS MALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Cornea, Hyperplasia		1 [2.0]			
Cornea, Inflammation	1 [2.0]	1 [3.0]			
Lens, Degeneration		1 [3.0]		1 [3.0]	
Retina, Atrophy		1 [3.0]	1 [3.0]	3 [2.3]	
Harderian Gland	(50)	(50)	(50)	(50)	
Infiltration Cellular, Lymphoid		1 [3.0]			
Inflammation	3 [1.3]	6 [1.5]		10 [1.3]	
Zymbal's Gland	(49)	(50)	(50)	(50)	
Hyperplasia	1 [4.0]		1 [1.0]		
URINARY SYSTEM				· · · · · · · · · · · · · · · · · · ·	
Kidney	(50)	(50)	(50)	(50)	
Accumulation, Hyaline Droplet	2 [2.0]	1 [1.0]			
Cyst			1	1	
Mineralization	44 [1.0]	37 [1.0]	38 [1.0]	49 [1.1]	
Nephropathy	49 [1.4]	49 [2.0]	48 [2.5]	49 [2.7]	
Pigmentation	24 [1.2]	46 [1.0]	37 [1.2]	44 [1.6]	
Papilla, Necrosis		2 [4.0]			
Pelvis, Dilatation				3 [2.3]	
Pelvis, Inflammation		3 [2.3]	1 [2.0]		
Pelvis, Transitional Epithelium, Hyperplasia	1 [2.0]	2 [1.0]	6 [1.7]	5 [1.0]	
Ureter	(0)	(0)	(0)	(1)	
Inflammation				1 [2.0]	
Urinary Bladder	(50)	(50)	(50)	(50)	
Hemorrhage		1 [3.0]	·	2 [3.0]	
Inflammation		2 [3.0]	2 [1.5]	2 [3.0]	
Ulcer		1 [4.0]			
Transitional Epithelium, Necrosis				1 [4.0]	

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 03	P18: INCIDENCE RATE	Date Report Requested: 02/28/2011			
Test Type: CHRONIC		Time Report Requested: 11:17:44			
Route: GAVAGE		CAS Numb	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Disposition Summary					
	50	50	50	50	
Animals Initially In Study	50	50	50	50	
Early Deaths Accidently Killed		4			
Dosing Accident		1		4	
Moribund Sacrifice	14	2	0	1 8	
Natural Death	3	3 4	8 9	o 18	
Survivors	5	4	J	10	
Terminal Sacrifice	33	42	33	23	
Animals Examined Microscopically	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Intestine Large, Cecum	(50)	(50)	(50)	(50)	
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Parasite Metazoan		1	()		
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Parasite Metazoan	4	4	3	3	
Intestine Small, Duodenum	(50)	(50)	(50)	(50)	
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	
Hyperplasia, Lymphoid		1 [3.0]	. /	- *	
Liver	(50)	(50)	(50)	(49)	
Angiectasis	1 [1.0]	4 [1.8]	10 [1.1]	5 [1.4]	
Basophilic Focus	46	45	5	6	
Clear Cell Focus	7	17	24	29	
Degeneration, Cystic			2 [1.0]	10 [1.2]	
Eosinophilic Focus	18	24	29	32	
Fatty Change, Focal	8 [1.4]	13 [1.2]	3 [1.3]	4 [1.3]	
Fatty Change, Diffuse	9 [1.6]	1 [1.0]	3 [2.7]	1 [3.0]	
Hematopoietic Cell Proliferation		-	2 [1.0]	2 [1.0]	
Hepatodiaphragmatic Nodule	3	6	5	3	
Inflammation	38 [1.1]	46 [1.0]	42 [1.0]	39 [1.1]	
Mixed Cell Focus	14	20	17	26	

		AVERAGE SEVE			
Test Type: CHRONIC		N,N-Dimeth	Time Report Requested: 11:17:44		
Route: GAVAGE		CAS Num	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Bile Duct, Cyst		1		1	
Bile Duct, Fibrosis	6 [1.2]	11 [1.0]	23 [1.0]	27 [1.1]	
Bile Duct, Hyperplasia	10 [1.6]	21 [1.0]	27 [1.0]	43 [1.5]	
Centrilobular, Degeneration	[]	[]	1 [2.0]	1 [2.0]	
Hepatocyte, Hypertrophy			6 [1.3]	22 [1.3]	
Hepatocyte, Necrosis			1 [2.0]	5 [1.8]	
Oval Cell, Hyperplasia	2 [2.0]		2 [1.5]	1 [1.0]	
Mesentery	(8)	(9)	(9)	(3)	
Fat, Necrosis	8 [3.0]	9 [3.0]	9 [3.0]	3 [3.0]	
Pancreas	(50)	(50)	(50)	(50)	
Cyst	5	4	5	5	
Fibrosis	1 [2.0]		0	0	
Infiltration Cellular, Mononuclear Cell	13 [1.5]	11 [1.1]	9 [1.6]	9 [1.2]	
Acinus, Atrophy	14 [1.4]	7 [1.7]	9 [1.2]	7 [1.6]	
Acinus, Hyperplasia		. []	0[]	1 [1.0]	
Duct, Fibrosis	1 [2.0]			.[]	
Duct, Inflammation, Chronic Active	.[=:0]	1 [3.0]			
Salivary Glands	(50)	(50)	(50)	(48)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Hyperplasia, Squamous	5 [1.8]	1 [1.0]	4 [1.8]	4 [2.3]	
Inflammation	5 [2.2]	1[1.0]	4 [2.0]	2 [2.5]	
Ulcer	5 [2.4]		3 [2.0]	2 [2.5]	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Inflammation	(00)	(00)	1 [1.0]	(00)	
Mineralization	1 [1.0]		.[]		
Ulcer	.[]		1 [3.0]		
Tongue	(1)	(0)	(0)	(2)	
Tooth	(0)	(1)	(0)	(0)	
Peridontal Tissue, Inflammation	(-)	1 [1.0]	(-)	(-)	
CARDIOVASCULAR SYSTEM					
Blood Vessel	(50)	(50)	(50)	(50)	
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	36 [1.1]	42 [1.1]	40 [1.1]	42 [1.1]	

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 02/28/2011

a - Number of animals examined microscopically at site and number of animals with lesion

b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No. 20107 - 03

TDMS No. 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44			
Test Type: CHRONIC					
Route: GAVAGE			yl-p-toluidine per: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N FISCHER 344 RATS FEMALE		Lab: BAT			
	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Pigmentation			1 [1.0]		
Thrombosis			.[]	1 [3.0]	
Endocardium, Hyperplasia		1 [2.0]		. []	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(49)	
Angiectasis	39 [1.8]	42 [1.7]	43 [1.6]	34 [1.5]	
Degeneration, Cystic	8 [2.0]	5 [1.0]	5 [1.0]	3 [2.0]	
Hyperplasia	26 [1.7]	24 [1.5]	28 [1.5]	12 [1.4]	
Hypertrophy	11 [1.7]	10 [1.2]	12 [1.9]	8 [1.4]	
Necrosis	1 [1.0]			1 [2.0]	
Pigmentation		1 [3.0]			
Vacuolization Cytoplasmic	26 [1.5]	26 [1.3]	26 [1.3]	18 [1.4]	
Adrenal Medulla	(50)	(50)	(50)	(49)	
Atrophy		1 [3.0]			
Hyperplasia	4 [1.5]	3 [1.7]	1 [3.0]	5 [1.8]	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Parathyroid Gland	(50)	(50)	(50)	(46)	
Hyperplasia, Focal			1 [2.0]		
Hyperplasia, Diffuse	1 [1.0]	2 [1.0]	2 [1.0]	5 [1.4]	
Pituitary Gland	(50)	(50)	(50)	(50)	
Cyst	11	20	15	4	
Fibrosis		1 [2.0]			
Pigmentation		1 [2.0]			
Pars Distalis, Angiectasis	1 [3.0]			1 [3.0]	
Pars Distalis, Cyst	4		2	1	
Pars Distalis, Hyperplasia	14 [2.5]	17 [2.6]	15 [2.5]	17 [2.6]	
Thyroid Gland	(49)	(47)	(47)	(45)	
C-cell, Hyperplasia	29 [1.5]	33 [1.4]	15 [1.0]	4 [1.5]	
Follicle, Cyst	1			- •	
Follicular Cell, Hyperplasia	1 [1.0]	1 [1.0]			

GENERAL BODY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

TDMS No. 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44				
Test Type: CHRONIC						
Route: GAVAGE			yl-p-toluidine b er: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04	
Species/Strain: RATS/F 344/N						
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG		
None						
GENITAL SYSTEM			·			
Clitoral Gland	(50)	(49)	(50)	(50)		
Cyst	11	8	7	5		
Hyperplasia	9 [1.6]	9 [2.0]	6 [2.2]	4 [2.0]		
Inflammation	22 [1.4]	26 [1.5]	20 [1.5]	15 [1.1]		
Ovary	(50)	(50)	(50)	(50)		
Atrophy		2 [2.0]				
Cyst	4	3	5			
Uterus	(50)	(50)	(50)	(50)		
Cyst	1					
Decidual Reaction			1 [3.0]			
Hemorrhage				2 [3.0]		
Inflammation	1 [1.0]		1 [2.0]			
Cervix, Cyst				1		
Endometrium, Hyperplasia, Cystic				2 [3.0]		
Myometrium, Fibrosis		1 [3.0]				
Vagina	(1)	(1)	(0)	(0)		
HEMATOPOIETIC SYSTEM						
Bone Marrow	(50)	(50)	(50)	(50)		
Hyperplasia	18 [2.8]	13 [2.5]	18 [2.7]	49 [2.6]		
Myelofibrosis	1 [2.0]			1 [3.0]		
Lymph Node	(2)	(1)	(2)	(1)		
Mediastinal, Ectasia	1 [2.0]	1 [2.0]	1 [2.0]	1 [3.0]		
Lymph Node, Mesenteric	(50)	(49)	(50)	(49)		
Hyperplasia, Lymphoid	1 [3.0]					
Infiltration Cellular, Histiocyte	30 [1.3]	29 [1.2]	35 [1.2]	33 [1.5]		
Spleen	(50)	(50)	(50)	(50)		
Congestion		9 [1.1]	26 [1.3]	28 [1.8]		
Hematopoietic Cell Proliferation	32 [1.6]	45 [1.8]	47 [1.9]	42 [1.7]		
Necrosis	2 [3.0]					

TDMS No. 20107 - 03	P18: INCIDENCE RATI	Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44			
Test Type: CHRONIC					
Route: GAVAGE		CAS Num	ber: 99-97-8		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Pigmentation	44 [2.0]	47 [2.1]	47 [2.5]	49 [2.2]	
Capsule, Fibrosis	8 [1.1]	[]	8 [1.1]	41 [1.3]	
Capsule, Hemorrhage	0[111]	1 [3.0]	0[111]	[]	
Capsule, Hypertrophy, Mesothelium	1 [1.0]	14 [1.0]	10 [1.0]	16 [1.1]	
Lymphoid Follicle, Atrophy	1 [2.0]	2 [3.0]	10[1.0]	28 [2.4]	
Red Pulp, Hyperplasia	1 [2.0]			20 [2.4]	
		1 [3.0]		(40)	
Thymus	(47)	(50)	(50)	(48)	
Atrophy	45 [2.6]	45 [2.2]	45 [2.3]	44 [2.4]	
INTEGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Cyst	4		3		
Hyperplasia	9 [1.2]	9 [1.1]	2 [1.0]		
Skin	(50)	(50)	(50)	(50)	
Cyst Epithelial Inclusion	ζ, γ	1 [3.0]			
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Hyperostosis	(88)	(00)	1 [2.0]	(00)	
Hyperedeele			· [2.0]		
NERVOUS SYSTEM					
Brain	(50)	(50)	(50)	(50)	
Hemorrhage	× ,	1 [2.0]	1 [3.0]		
Hydrocephalus		1 [2.0]	[- · -]		
Peripheral Nerve	(0)	(0)	(1)	(0)	
Spinal Cord	(0)	(0)	(1)	(0)	
	(0)	(0)	('/	(~)	
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	

TDMS No	. 20107 - 03
---------	--------------

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 02/28/2011 AVERAGE SEVERITY GRADES[b]

Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344/N		N,N-Dimeth CAS Numl	Time Report Requested: 11:17:44 First Dose M/F: 10/20/04 / 10/21/04 Lab: BAT		
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
Congestion				2 [2.0]	
Fibrosis	1 [2.0]				
Inflammation	3 [1.3]			1 [1.0]	
Metaplasia, Squamous	2 [1.5]				
Alveolar Epithelium, Hyperplasia	5 [1.8]	2 [2.5]	2 [2.0]	2 [1.5]	
Alveolus, Infiltration Cellular, Histiocyte	11 [1.0]	10 [1.0]	11 [1.0]	17 [1.0]	
Nose	(50)	(49)	(50)	(49)	
Foreign Body	3	8	1	4	
Inflammation	23 [1.3]	24 [1.4]	22 [1.1]	45 [1.5]	
Glands, Hyperplasia				1 [1.0]	
Glands, Olfactory Epithelium, Dilatation				48 [2.4]	
Glands, Olfactory Epithelium, Hyperplasia			4 [1.0]	47 [1.9]	
Glands, Olfactory Epithelium, Metaplasia				42 [1.3]	
Glands, Olfactory Epithelium, Necrosis				18 [2.8]	
Glands, Respiratory Epithelium, Dilatation	5 [1.0]	12 [1.0]	27 [1.1]	47 [1.2]	
Glands, Respiratory Epithelium, Hyperplasia	6 [1.2]	9 [1.0]	22 [1.3]	45 [1.6]	
Glands, Respiratory Epithelium, Metaplasia, Respiratory	17 [1.1]	33 [1.1]	44 [1.8]	47 [2.0]	
Glands, Transitional Epithelium, Dilatation				9 [1.4]	
Glands, Transitional Epithelium, Hyperplasia		4 [1.0]	12 [1.2]	24 [1.4]	
Nasolacrimal Duct, Inflammation	1 [3.0]				
Nerve, Atrophy				4 [1.8]	
Olfactory Epithelium, Accumulation, Hyaline Droplet	43 [1.7]	42 [2.1]	38 [1.6]		
Olfactory Epithelium, Degeneration			1 [1.0]	46 [2.0]	
Olfactory Epithelium, Hyperplasia, Basal Cell				25 [1.2]	
Olfactory Epithelium, Metaplasia, Respiratory	4 [1.5]	6 [1.5]	1 [2.0]	21 [1.2]	
Olfactory Epithelium, Metaplasia, Squamous				2 [1.5]	
Respiratory Epithelium, Accumulation, Hyaline Droplet	35 [1.4]	30 [1.2]	23 [1.1]	2 [1.0]	
Respiratory Epithelium, Hyperplasia	10 [1.0]	13 [1.4]	11 [1.1]	41 [1.3]	
Transitional Epithelium, Degeneration				1 [1.0]	
Transitional Epithelium, Hyperplasia		1 [1.0]	6 [1.0]	33 [1.1]	
Trachea	(50)	(50)	(50)	(50)	
Inflammation				1 [2.0]	
Inflammation, Suppurative				1 [1.0]	
Perforation				1	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 20107 - 03	P18: INCIDENCE RATE	I Date Report Requested: 02/28/2011 Time Report Requested: 11:17:44			
Test Type: CHRONIC					
Route: GAVAGE		N,N-Dimethy CAS Numb	•		First Dose M/F: 10/20/04 / 10/21/04
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	
SPECIAL SENSES SYSTEM					
Ear	(1)	(0)	(0)	(1)	
Eye	(50)	(50)	(50)	(50)	
Cataract	3 [3.0]	2 [3.5]	3 [3.0]	(00)	
Ciliary Body, Cornea, Inflammation	3 [3.0] 1 [4.0]	2 [0.0]	0 [0.0]		
Cornea, Degeneration	· [+.0]			1 [2.0]	
Retina, Atrophy	2 [3.5]	3 [3.0]	3 [3.0]	1 [3.0]	
Harderian Gland	2 [3.5] (50)	3 [3.0] (50)	(50)	(50)	
Inflammation					
Lacrimal Gland	6 [1.7] (0)	4 [1.5] (0)	2 [1.0] (0)	1 [1.0] (1)	
URINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
-				4 [4 0]	
Accumulation, Hyaline Droplet	25 [1.2]	23 [1.1]	5 [1.0]	1 [1.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only	25 [1.2]	23 [1.1]	5 [1.0] 1	1 [1.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst		23 [1.1] 1	1	1	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct	4 [2.3]	1	1 5 [2.0]	1 2 [3.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization	4 [2.3] 33 [1.1]	1 35 [1.0]	1 5 [2.0] 35 [1.1]	1 2 [3.0] 37 [1.1]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy	4 [2.3] 33 [1.1] 28 [1.1]	1 35 [1.0] 38 [1.2]	1 5 [2.0] 35 [1.1] 38 [1.2]	1 2 [3.0] 37 [1.1] 41 [1.8]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0]	1 35 [1.0]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0]	1 2 [3.0] 37 [1.1]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0]	1 35 [1.0] 38 [1.2]	1 5 [2.0] 35 [1.1] 38 [1.2]	1 2 [3.0] 37 [1.1] 41 [1.8]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0]	1 35 [1.0] 38 [1.2]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0]	1 35 [1.0] 38 [1.2]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0] 1 [2.0]	1 35 [1.0] 38 [1.2] 45 [1.0]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0] 1 [1.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0] 1 [2.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0]	1 35 [1.0] 38 [1.2]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0] 1 [2.0]	1 35 [1.0] 38 [1.2] 45 [1.0]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0] 1 [1.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0] 1 [2.0]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation Pelvis, Inflammation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0] 1 [2.0] 3 [1.7]	1 35 [1.0] 38 [1.2] 45 [1.0] 3 [2.3]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0] 1 [1.0] 9 [2.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0] 1 [2.0] 5 [2.6]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation Pelvis, Inflammation Pelvis, Transitional Epithelium, Hyperplasia	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0] 1 [2.0] 3 [1.7] 2 [2.0]	1 35 [1.0] 38 [1.2] 45 [1.0] 3 [2.3]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0] 1 [1.0] 9 [2.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0] 1 [2.0] 5 [2.6]	
Accumulation, Hyaline Droplet Calculus Micro Observation Only Cyst Infarct Mineralization Nephropathy Pigmentation Papilla, Fibrosis Papilla, Inflammation Papilla, Necrosis Pelvis, Dilatation Pelvis, Inflammation Pelvis, Transitional Epithelium, Hyperplasia Renal Tubule, Dilatation	4 [2.3] 33 [1.1] 28 [1.1] 41 [1.0] 1 [2.0] 1 [2.0] 3 [1.7] 2 [2.0] 1 [2.0]	1 35 [1.0] 38 [1.2] 45 [1.0] 3 [2.3]	1 5 [2.0] 35 [1.1] 38 [1.2] 43 [1.0] 1 [1.0] 9 [2.0]	1 2 [3.0] 37 [1.1] 41 [1.8] 49 [1.4] 1 [3.0] 1 [2.0] 5 [2.6]	

TDMS No. 20107 - 03	P18: INCIDENCE RATE	Date Report Requested: 02/28/2011			
Test Type: CHRONIC		Time Report Requested: 11:17:44			
Route: GAVAGE	First Dose M/F: 10/20/04 / 10/21/04				
Species/Strain: RATS/F 344/N					Lab: BAT
FISCHER 344 RATS FEMALE	0 MG/KG	6 MG/KG	20 MG/KG	60 MG/KG	

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)